Policy · 116th Congress
FDA revokes authorization for drugs Trump touted for COVID-19
“The known and potential benefits of CQ and HCQ no longer outweigh the known and potential risks for the authorized use,” FDA Chief Scientist Denise M. Hinton wrote in a letter to Gary L.